Leukemia Clinical Trials in Massachusetts

Showing 1021-1040 of 1,253 trials

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

NCT01323920

A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD. In this research study, we are studying the safety and effectiveness of a bortezomib based GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call transplantation from a matched unrelated donor, mismatched related or unrelated donor.

LeukemiaLymphomaMyelodysplastic Syndrome

Dana-Farber Cancer Institute35 participantsStarted May 2011

Boston, Massachusetts, United States

COMPLETEDPhase 126 miles

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474

RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host disease in patients with hematologic cancer or other disease undergoing donor stem cell transplant.

Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more

Massachusetts General Hospital46 participantsStarted Jan 2008

Boston, Massachusetts, United States

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Leukemia Trials in Other Cities

Efficacy Study on Silver-coated ETT Cleaned With a Novel Device

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Mouse Allergen and Asthma Intervention Trial

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Alisertib for Acute Myeloid Leukemia

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)

Other Conditions in Massachusetts